Welcome to the e-CCO Library!

P406: Disease clearance in patients with ulcerative colitis treated with aminosalicylates
Year: 2022
Source: ECCO'22
Authors: Nascimento, C.(1);Revés, J.(1);Roque Ramos, L.(1);Carolina, P.(1);Fidalgo, C.(1);Glória, L.(1);Torres, J.(1);
Created: Friday, 11 February 2022, 3:52 PM
P406: General health status in patients with moderate to severe ulcerative colitis receiving ustekinumab: results from the Phase 3 UNIFI induction and maintenance studies
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Danese*1, B. E. Sands2, R. W. Leong3,4, H. Zhang5, J. Johanns5, P. Szapary5, C. Marano5, C. Han6

Created: Friday, 22 February 2019, 9:41 AM
P406: Malnutrition during hospitalisation for acute severe IBD is associated with increased risk of relapse
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Kulmala1*, J. Björk2, S. Andersson3, A.-S. Backman1,2, C.R.H. Hedin2, F. Bresso2

Created: Thursday, 21 February 2019, 9:14 AM
P406: Observational study of the effectiveness of vedolizumab on treatment outcomes and health-related quality of life in biologic-naïve patients with Inflammatory Bowel Diseases in Greece – the TROVE study - Interim Analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Chatzinikolaou-, M.L.(1)*;Kifnidi, C.(2);Kokkotis, G.(1);Gatopoulou, A.(3);Michopoulos, S.(4);Soufleris, K.(5);Poulopoulos, G.(6);Theodoropoulou, A.(7);Mantzaris, G.(8);Ntelis, V.(9);Papatheodoridis, G.(10);Tzouvala, M.(11);Koutroubakis, I.E.(12);Theocharis, G.(13);Kourikou, A.(14);Christodoulou, D.(15);Grammatopoulos, A.(16);Michalopoulos, G.(17);Georgopoulos, S.(18);Akriviadis, E.(19);Vradelis, S.(20);Gkagkari, V.(4);Zampeli, E.(4);Fasoulas, K.(5);Charalampidis, M.(6);Velegraki, M.(7);Karampekos, G.(8);Viazis, N.(8);Andrianakou , G.(9);Karatzas, P.(10);Tribonias, G.(11);Zacharopoulou, E.(11);Orfanoudaki, E.(12);Tsellou, E.(2);Psyrilos, A.(2);Roussou, D.(2);Bamias, G.(1);
Created: Friday, 14 July 2023, 11:05 AM
P407 Is the rapid infliximab infusion a safe and cost-saving strategy in paediatric inflammatory bowel disease?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Pujol Muncunill1, J. Martínez-Osorio1, F. Bossacoma-Busquets2, L. Álvarez-Carnero1, J. Arrojo-Juárez2, V. Vila-Miravet1, F.J. Martin De Carpi1

Created: Thursday, 30 January 2020, 10:12 AM
P407: A Phase IB/IIA study of remestemcel-L, an allogeneic bone marrow derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: An interim analysis
Year: 2022
Source: ECCO'22
Authors: Lightner, A.(1);Dadgar, N.(2);Fulmer, C.(3);Ream, J.(4);Nachand, D.(4);Steele, S.(2);
Created: Friday, 11 February 2022, 3:52 PM
P407: Clinical manifestations of thiopurine S-methyltransferase variants in Korean paediatric patients with inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Kim*

Created: Friday, 22 February 2019, 9:49 AM
P407: Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Peyrin-Biroulet, L.(1,2)*;Dubinsky, M.C.(3);Sands, B.E.(4);Panés, J.(5);Schreiber, S.(6);Reinisch, W.(7);Feagan, B.G.(8);Danese, S.(9);Yarur, A.(10);D'Haens, G.(11);Goetsch, M.(12);Wosik, K.(13);Wu, J.(14);Modesto, I.(15);McDonnell, A.(16);Bartolome, L.(17);Rabbat, C.J.(18);Vermeire, S.(19);
Created: Friday, 14 July 2023, 11:05 AM
P407: Faecal calprotectin predicts sustained treatment response of infliximab induction therapy superior to C-reactive protein and clinical activity scores in inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

P.M. Hellström1*, M. Lonnkvist2, H.O. Diaz Tartera1, R. Befrits2, M. Holst3

Created: Thursday, 21 February 2019, 9:14 AM
P407: Prospective evaluation of clinical efficacy and safety of golimumab in biologic experienced and naïve patients with moderate to severe ulcerative colitis: experience from a tertiary referral centre
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Orlandini B., Dragoni G., Bagnoli S., Deiana S., Macrì G., Rogai F.

Created: Wednesday, 20 February 2019, 10:36 AM
P407: Real-world safety of tofacitinib in inflammatory bowel diseases: a multi-centre study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Yarur*1, L. Bixuan1, P. Deepak2, A. Khatiwada2, G. Christophi2, M. Ciorba2, R. Ungaro3, M. Fenster3, C. Dimopoulos3, G. Syal4, R. Hirten3, J-F. Colombel3, C. Ha4, R. Weisshof5, J. Pekow5, A. Patel6, P. Beniwal-Patel1, B. Cohen3

Created: Friday, 22 February 2019, 9:41 AM
P407: Thiopurines: use them or lose them? Results of an international survey
Year: 2021
Source: ECCO'21 Virtual
Authors: Sousa, P.C.(1);Ministro, P.(2);Armuzzi, A.(3,4);Dignass, A.(5);Høivik, M.L.(6);Magro, F.(7,8,9);
Created: Wednesday, 2 June 2021, 4:12 PM
P408 Long-term impact of the decrease of infliximab trough levels on the disease course in Inflammatory Bowel Disease patients under maintenance treatment with infliximab
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Orfanoudaki1, M. Gazouli2, K. Foteinogiannopoulou1, E. Theodoraki1, E. Legaki2, I. Koutroubakis1

Created: Thursday, 30 January 2020, 10:12 AM
P408: Anti-Drug Antibodies Detected in the Presence of Adequate Infliximab Drug Levels In IBD Patients in Clinical Remission have Limited Clinical Significance
Year: 2021
Source: ECCO'21 Virtual
Authors: Doherty, J.(1);Varley, R.(1);Healy, M.(2);Dunne, C.(1);Mac Carthy, F.(1);McKiernan, S.(1);Hartery, K.(1);Kevans, D.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P408: Are pharmacokinetics more unfavourable in inflammatory bowel disease patients aged over 60 years?
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

L. Rinaldi1, N. Williet*2, E. Del tedesco2, c. Jarlot3, J. M. Phelip2, s. Paul4, X. Roblin3

Created: Friday, 22 February 2019, 9:49 AM
P408: Dual therapy with vedolizumab and tofacitinib in refractory ulcerative colitis patients – single centre experience
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kolar, M.(1);Kastylova, K.(1);Lukas, M.(1);Duricova, D.(1);Hruba, V.(1);Machkova, N.(1);Cerna, K.(1);Jirsa, J.(1);Kubickova, K.(1);Vojtechova, G.(1);Lukás, M.(1)*;
Created: Friday, 14 July 2023, 11:05 AM
P408: Faecal infliximab and disease activity in Acute Severe Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Shields, S.(1);Dunlop, A.(2);Gerasimidis, K.(3);Nichols, B.(3);Galloway, P.(2);Macdonald, J.(1);Hansen, R.(4);Seenan, J.P.(1);
Created: Friday, 11 February 2022, 3:52 PM
P408: Intestinal failure in Crohn’s disease: A case–control study
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Soop1*, A. Bond2, E. Nixon2, A. Teubner1, A. Abraham1, G. Carlson1, S. Lal2

Created: Thursday, 21 February 2019, 9:14 AM
P408: Long-term efficacy of infliximab in patients with ulcerative colitis – an observational study from a single center in Norway
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lerang F., Henriksen M., Jelsness-Jørgensen L.-P.

Created: Wednesday, 20 February 2019, 10:36 AM
P408: Switching from infliximab originator to a biosimilar does not affect efficacy, pharmacokinetics and immunogenicity in paediatric patients with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. van Hoeve*1,2, E. Dreesen3, I. Hoffman1, M. Ferrante2,4, A. Gils3, S. Vermeire2,4

Created: Friday, 22 February 2019, 9:41 AM